Section Arrow
FGEN.NASDAQ
- FibroGen
Quotes are at least 15-min delayed:2024/05/19 12:10 EDT
Last
 1.2
-0.04 (-3.23%)
Day High 
1.33 
Prev. Close
1.24 
1-M High
1.74 
Volume 
1.31M 
Bid
1.21
Ask
1.28
Day Low
1.195 
Open
1.24 
1-M Low
0.90105 
Market Cap 
123.35M 
Currency USD 
P/E -- 
%Yield
10-SMA 1.2 
20-SMA 1.15 
50-SMA 1.59 
52-W High 19.47 
52-W Low 0.3333 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.44/-1.56
Enterprise Value
261.82M
Balance Sheet
Book Value Per Share
-2.29
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
147.75M
Operating Revenue Per Share
1.56
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
NBYNovaBay Pharmaceuticals0.1186-0.0014-1.17%-- 
SCPXScorpius Holdings0.1035+0.0034+3.40%-- 
JAGXJaguar Health0.2585-0.0282-9.84%-- 
DNAGinkgo Bioworks Holdings0.8056-0.0334-3.98%-- 
ONCOOnconetix0.156+0.015+10.64%-- 
Quotes are at least 15-min delayed:2024/05/19 12:10 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.